- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07408856
CAN1012 in OED, DCIS e LCIS.
Uno studio di Fase I/Ib che valuta l'agonista TLR7 intralesionale, CAN1012, nella displasia epiteliale orale, nel carcinoma duttale in situ e nel carcinoma lobulare in situ
This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
This is not a dose finding study, and therefore patients may be enrolled to any of the four arms in any order, based on clinical considerations (e.g. OR scheduling). No arm, per specific disease type, may expand beyond the first 3 patients, until 30-day post-op safety evaluation has been completed. Study analysis is planned after a single dose of intralesional CAN1012.
The primary objective of this trial is to examine the safety of CAN1012 delivered by intralesional injection ahead of planned surgical resection. The study will be stopped early for patient safety according to stopping rules below. The sample size for the study is not based on any statistical assumptions. The number of subjects is based on the number of cohorts tested and the size of each cohort.
The Safety Analysis Set will consist of all subjects who receive at least one dose of study treatment. The Safety Analysis Set will be used for safety analyses.
The Intent-to-treat (ITT) Analysis Set will consist of all subjects who receive at least one dose of study treatment and have at least one post-Baseline assessment of tumor response.
The disposition of subjects will be summarized by presenting the number of subjects enrolled, the number and percentage of subjects in each analysis population, the number for whom the study drug was discontinued with the reasons for discontinuation, and the number of subjects who discontinued participation in the study with the reason(s) for withdrawal.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Isa Ngirailemesang, RN
- Numero di telefono: 503-215-1979
- Email: canrsrchstudies@providence.org
Luoghi di studio
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97213
- Reclutamento
- Providence Portland Cancer Institute - Franz Clinic
-
Sub-investigatore:
- Rom Leidner, MD
-
Sub-investigatore:
- Matthew Taylor, MD
-
Sub-investigatore:
- David Page, MD
-
Sub-investigatore:
- Alison Conlin, MD
-
Sub-investigatore:
- Roxanne Griswold, NP
-
Sub-investigatore:
- Rui Li, MD, PhD
-
Sub-investigatore:
- RaYoung Chung, NP
-
Sub-investigatore:
- Amy Hartman, NP
-
Sub-investigatore:
- Molly Davis, NP
-
Sub-investigatore:
- Brendan Curti, MD
-
Sub-investigatore:
- Rachel Sanborn, MD
-
Contatto:
- Isa Ngirailemesang, RN
- Numero di telefono: 503-215-1979
- Email: canrsrchstudies@providence.org
-
Investigatore principale:
- Sasha Stanton, MD, PhD
-
Sub-investigatore:
- Mary Martel, NP
-
Sub-investigatore:
- Jamie Martinez, NP
-
Sub-investigatore:
- Binbin Zheng, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Male or female patients with DCIS or LCIS found on core biopsy.
-
Tumor types allowed:
Biopsy-identified DCIS or LCIS comprising a single lesion ≥ 1 cm and ≤ 5 cm in size by imaging (mammogram or MRI or ultrasound (US)) without evidence of invasive disease on the biopsy and US negative for suspicious ipsilateral lymph nodes.
-
Age 18 years or above with ability to give informed consent, comply with the protocol, and sign a study-specific consent document.
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1 deemed suitable by investigator or designee for requirements of study.
-
Laboratory values within 72 hours of Day 0:
- WBC ≥ 2.0 K/µL, ANC ≥ 1.0 K/µL
- Hgb ≥ 10 g/dL
- Platelets ≥ 100,000 K/µL
- Creatinine Clearance (using Cockcroft-Gault) ≥ 60.
- AST/ALT ≤ 2.5 x ULN
- Total bilirubin ≤ 3 x ULN, (except subjects with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
- Negative pregnancy test for people of childbearing potential (bHCG urine or serum)
-
Patients and their partners who are capable of conceiving must agree to use effective methods of contraception (non-hormonal only) during the course of treatment and for 165 days after last dose of CAN1012.
Exclusion Criteria:
- Any serious underlying medical or psychiatric condition that, in the opinion of the investigator, would pose a risk to patient safety or interfere with the study procedures, completion, or evaluation.
- Need for corticosteroids ≥ 10mg prednisone daily equivalent; inhaled steroids are acceptable.
- Need for hormonal contraception including oral contraceptives, implant, injectable depots, vaginal rings, skin patches, and the progestin IUD; or any medication that is a sensitive substrate of the major CYPs.
- History of or current active autoimmune diseases which, in the judgment of the investigator, pose an active and significant risk. Vitiligo, lichen planus or lichenoid inflammation, and adequately controlled endocrine deficiencies such as hypothyroidism/hyperthyroidism are not exclusionary.
- Previous history of bone marrow transplantation or oral Graft Versus Host Disease (GVHD).
- Has an active infection requiring systemic therapy. Investigator may allow if deemed not clinically significant.
- Has active or uncontrolled Hepatitis B, Hepatitis C, or HIV with AIDS (acquired immunodeficiency syndrome)- defined opportunistic infection.
- Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known history of Hepatitis C virus (defined as HCV RNA) infection. Testing for Hepatitis B and Hepatitis C is not required unless mandated by local health authority.
- Has a baseline electrocardiogram (ECG) with a prolonged QTc interval > 480 msec. Medications which have a known and clinically significant risk of QT prolongation may be allowed per investigator discretion.
- Patients who have had a history of acute diverticulitis, intra-abdominal abscess, GI obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation, and in the judgment of the investigator still pose an active risk.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Arm A: Day 2-3
Injection of CAN1012 into target lesion will occur on Day 0. Specimens collected during Standard of Care (SOC) resection will be evaluated for immunologic changes compared to baseline on Days 2-3. |
CAN1012 is a IFN-a biased, long-acting, highly selective TLR7 agonist, which acts as an immune modulator capable of priming both innate and adaptive immunity against tumors. CAN1012 will be administered as an injection directly into the target lesion prior to surgery. |
|
Sperimentale: Arm B: Day 5-7
Injection of CAN1012 into target lesion will occur on Day 0. Specimens collected during Standard of Care (SOC) resection will be evaluated for immunologic changes compared to baseline on Days 5-7. |
CAN1012 is a IFN-a biased, long-acting, highly selective TLR7 agonist, which acts as an immune modulator capable of priming both innate and adaptive immunity against tumors. CAN1012 will be administered as an injection directly into the target lesion prior to surgery. |
|
Sperimentale: Arm C: Day 9-11
Injection of CAN1012 into target lesion will occur on Day 0. Specimens collected during Standard of Care (SOC) resection will be evaluated for immunologic changes compared to baseline on Days 9-11. |
CAN1012 is a IFN-a biased, long-acting, highly selective TLR7 agonist, which acts as an immune modulator capable of priming both innate and adaptive immunity against tumors. CAN1012 will be administered as an injection directly into the target lesion prior to surgery. |
|
Sperimentale: Arm D: Day 13-15
Injection of CAN1012 into target lesion will occur on Day 0. Specimens collected during Standard of Care (SOC) resection will be evaluated for immunologic changes compared to baseline on Days 13-15. |
CAN1012 is a IFN-a biased, long-acting, highly selective TLR7 agonist, which acts as an immune modulator capable of priming both innate and adaptive immunity against tumors. CAN1012 will be administered as an injection directly into the target lesion prior to surgery. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Safety of CAN1012
Lasso di tempo: Post-operative follow-up visit (30 days after surgery)
|
Safety will be measured by demonstrating that there is a less than 33% rate of delayed surgery attributable to the study treatment. |
Post-operative follow-up visit (30 days after surgery)
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Sasha Stanton, MD, PhD, Providence Health & Services
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie, ghiandolari ed epiteliali
- Adenocarcinoma
- Malattie della pelle
- Malattie del seno
- Carcinoma
- Neoplasie duttali, lobulari e midollari
- Neoplasie mammarie
- Carcinoma in situ
- Malattie della pelle e del tessuto connettivo
- Carcinoma mammario in situ
- Carcinoma, intraduttale, non infiltrante
Altri numeri di identificazione dello studio
- 2025001065
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .